silevertinib in combination with temozolomide

Phase 2

silevertinib in combination with temozolomide is one of 4 therapeutic programs targeting Glioblastoma (GBM). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Glioblastoma (GBM)Recruiting

Glioblastoma (GBM)Phase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Glioblastoma (GBM)

#DrugCompanyPhaseTrials

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 2

DOC1021

DDiakonos Oncology Corporation

Phase 2

1 3

Temodar

DDiakonos Oncology Corporation

Phase 2

1 4

silevertinib in combination with temozolomide

BBlack Diamond Therapeutics, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2Recruiting

Glioblastoma (GBM)

NCT07326566

Clinical

Trials by Indication[1]

Glioblastoma (GBM)1 trial

A Phase 2 Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Silevertinib, an Oral EGFR Inhibitor, in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter and EGFRvIII

Recruiting·BBlack Diamond Therapeutics, Inc.·Phase 2·NCT07326566·162 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for silevertinib in combination with temozolomide. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for silevertinib in combination with temozolomide. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Black Diamond Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: BBlack Diamond Therapeutics, Inc.

silevertinib in combination with temozolomide

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Glioblastoma (GBM)1 trial

References

Drug Info

Quick Facts

Related News